Remicade behind Mitsubishi Tanabe's first-half growth
This article was originally published in Scrip
Executive Summary
Remicade (infliximab; licensed from Johnson & Johnson) was again the star performer at Japan's Mitsubishi Tanabe Pharma (MTP) in the first half to 30 September, in which sales of the TNF-targeting antibody rose by 29% to ¥29.3 billion ($364.0 million).